Evidence map›Paper›PMID 26110795›Full record

ReviewCurrent opinion in neurology2015

Imaging pathological tau in atypical parkinsonian disorders.

Sarah Coakeley, Antonio P Strafella

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Frontiers in aging neuroscience · 2017
    Article
  2. Neuroimaging of Parkinson's disease: Expanding views.Neuroscience and biobehavioral reviews · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Sarah CoakeleyaMorton and Gloria Shulman Movement Disorder Unit and Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Health Network bResearch Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health cDivision of Brain, Imaging, and Behaviour - Systems Neuroscience, Toronto Western Research Institute, University Health Network, University of Toronto, Ontario, Canada.
Antonio P Strafella
Mental Health Research Institute · AUUniversity Health Network · CA

Funding

CIHR 136778-1CIHR MOP 136778
6 · The paper itself

Abstract

purpose of reviewThis review examines the current literature on tau imaging in atypical parkinsonian disorders and other tauopathies. RECENT

findingsThere are a number of tau PET radiotracers that have demonstrated promising preliminary results in atypical parkinsonian disorders, such as progressive supranuclear palsy and corticobasal degeneration. These radiotracers were capable of selectively labeling tau in vitro and in vivo, with high affinity. Other radiotracers tested more extensively in patients with Alzheimer's disease have also been able to successfully image tau deposition. SUMMARY: The development of tau radioligands for PET has led to the current testing of these tracers in clinical studies, many of which concentrate on patients with Alzheimer's disease. Atypical parkinsonian disorders such as progressive supranuclear palsy and corticobasal degeneration are now being investigated as well. These disorders can be very difficult to diagnose, because of their clinical overlap with other parkinsonian disorders. Imaging tau using PET could serve as a diagnostic biomarker for these tauopathies and provide a means of assessing treatment that targets tau burden.

Indexed as

BrainHumansNeuroimagingParkinsonian DisordersRadionuclide Imagingtau Proteinstau Proteins

Identifiers

PMID26110795
PMCPMC4874783
OpenAlexW2418466681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.